Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Novo Nordisk A/S389 enrolled

Overview

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

389

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

insulin glargineDRUG

insulin aspartDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 Diabetes for more than 12 months * Currently treated with glucose lowering tablets or insulin * HbA1c: 7.0-12.0%

Locations (78)

Outcomes

Primary Outcomes

HbA1c

Time frame: after 26 weeks

Secondary Outcomes

Body weight

Glucose profiles

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.